Compare NHI & CRNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NHI | CRNX |
|---|---|---|
| Founded | 1991 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.9B |
| IPO Year | 1994 | 2018 |
| Metric | NHI | CRNX |
|---|---|---|
| Price | $72.95 | $84.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | ★ $87.00 | $76.75 |
| AVG Volume (30 Days) | 369.1K | ★ 2.8M |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.81% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.97 | N/A |
| Revenue | ★ $375,628,000.00 | $1,039,000.00 |
| Revenue This Year | $15.44 | $720.10 |
| Revenue Next Year | $10.01 | $184.67 |
| P/E Ratio | $36.18 | ★ N/A |
| Revenue Growth | ★ 12.07 | N/A |
| 52 Week Low | $67.94 | $28.73 |
| 52 Week High | $91.38 | $84.71 |
| Indicator | NHI | CRNX |
|---|---|---|
| Relative Strength Index (RSI) | 44.00 | 90.48 |
| Support Level | $68.92 | $83.47 |
| Resistance Level | $73.60 | N/A |
| Average True Range (ATR) | 2.23 | 0.26 |
| MACD | -0.65 | -1.47 |
| Stochastic Oscillator | 36.69 | 97.58 |
National Health Investors Inc is a self-managed REIT that owns, leases, operates, and finances the development of senior housing communities and medical facilities. It operates through two segments: Real Estate Investments and Senior Housing Operating Portfolio (SHOP). The Real Estate Investments segment, which generates the majority of revenue, includes real estate leases, mortgages, and other notes receivable related to independent living facilities, assisted living facilities, entrance fee communities, senior living campuses, skilled nursing facilities, and a hospital. The SHOP segment consists of ventures that own and operate independent living facilities. The company's revenues are derived from rental income, interest and other income, and resident fees and services.
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.